MD4300C1 - Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel - Google Patents

Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel

Info

Publication number
MD4300C1
MD4300C1 MDA20120128A MD20120128A MD4300C1 MD 4300 C1 MD4300 C1 MD 4300C1 MD A20120128 A MDA20120128 A MD A20120128A MD 20120128 A MD20120128 A MD 20120128A MD 4300 C1 MD4300 C1 MD 4300C1
Authority
MD
Moldova
Prior art keywords
liver cancer
cell proliferation
inhibitor
hepg2 cell
thiosemicarbazono
Prior art date
Application number
MDA20120128A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD4300B1 (en
Inventor
Аурелиан ГУЛЯ
Анжела ЖАЛБЭ
Виктор ЦАПКОВ
Серджиу ШОВА
Дональд ПОЙРИЕР
Алена КОТОВАЯ
Original Assignee
Государственный Университет Молд0
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственный Университет Молд0 filed Critical Государственный Университет Молд0
Priority to MDA20120128A priority Critical patent/MD4300C1/en
Publication of MD4300B1 publication Critical patent/MD4300B1/en
Publication of MD4300C1 publication Critical patent/MD4300C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to chemistry, namely to the synthesis of coordinative compounds from the class of thiosemicarbazonates of transition metals and can be used in medicine as cytostatic agent in the prophylaxis and treatment of liver cancer.Summary of the invention consists in the fact that as inhibitor of HepG2 cell proliferation in liver cancer is proposed the use of a new compound, chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel of formula:The claimed compound exhibits itself as an effective inhibitor of HepG2 cell proliferation in liver cancer at concentrations of 10-5…10-6 mol/L.
MDA20120128A 2012-12-28 2012-12-28 Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel MD4300C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20120128A MD4300C1 (en) 2012-12-28 2012-12-28 Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20120128A MD4300C1 (en) 2012-12-28 2012-12-28 Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel

Publications (2)

Publication Number Publication Date
MD4300B1 MD4300B1 (en) 2014-08-31
MD4300C1 true MD4300C1 (en) 2015-03-31

Family

ID=51485231

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20120128A MD4300C1 (en) 2012-12-28 2012-12-28 Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel

Country Status (1)

Country Link
MD (1) MD4300C1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4407C1 (en) * 2015-04-29 2016-10-31 Государственный Университет Молд0 Inhibitor of human myeloid leukemia HL-60 cells based on bis[N-(prop-2-en-1-yl)-2-(pyridine-2-ylmethylidene)hydrazinecarbothioamide]nickel(II) chloride hydrate

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD891G2 (en) * 1996-06-24 1998-07-31 Николае ЕРЕМИЯ Method for animals immunologic system potentiation remedy
CN101205233A (en) * 2007-12-14 2008-06-25 中国科学院南海海洋研究所 Dimeric flavone compound as well as preparation and uses thereof
CN101204401A (en) * 2007-12-14 2008-06-25 中国科学院南海海洋研究所 Sea hedgehog extractive, preparation method and anticancer application thereof
CN101333236A (en) * 2008-08-05 2008-12-31 浙江大学 Method for preparing clitocine and applications in antineoplastic medicaments
RU2008144584A (en) * 2006-04-12 2010-05-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) 4,5-DIHYDRO- [1,2,4] TRIAZOLO [4,3-F] PERIDINES AS PLK1 PROTEINKINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CN102038934A (en) * 2005-11-03 2011-05-04 福建医科大学 Application of cucurmosin in preparation of drug for treating breast cancer
CN102219822A (en) * 2011-03-24 2011-10-19 上海交通大学 Ganoderic acid T amide derivative TLTO-A and synthetic method and application thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD891G2 (en) * 1996-06-24 1998-07-31 Николае ЕРЕМИЯ Method for animals immunologic system potentiation remedy
CN102038934A (en) * 2005-11-03 2011-05-04 福建医科大学 Application of cucurmosin in preparation of drug for treating breast cancer
RU2008144584A (en) * 2006-04-12 2010-05-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) 4,5-DIHYDRO- [1,2,4] TRIAZOLO [4,3-F] PERIDINES AS PLK1 PROTEINKINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CN101205233A (en) * 2007-12-14 2008-06-25 中国科学院南海海洋研究所 Dimeric flavone compound as well as preparation and uses thereof
CN101204401A (en) * 2007-12-14 2008-06-25 中国科学院南海海洋研究所 Sea hedgehog extractive, preparation method and anticancer application thereof
CN101333236A (en) * 2008-08-05 2008-12-31 浙江大学 Method for preparing clitocine and applications in antineoplastic medicaments
CN102219822A (en) * 2011-03-24 2011-10-19 上海交通大学 Ganoderic acid T amide derivative TLTO-A and synthetic method and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Mohammad M. Hassanien, Wael I. Mortada, Ali M. Hassan, Ahmed A. El-Asmy Synthesis, characterization and biological activities of 4-(p-chlorophenyl)-1-(pyridine-2-yl)thiosemicarbazibe and its metal complexes. Journal of the Korean Chemical Society, 2012, vol. 56. Nr. 6. p. 679 - 691 *
Poma P., Notarbartolo M ., Labbozzetta M., Sanguedolce R., Alaimo A., Carina V., Maurici A., Cusimano A., Cervello M., D'Alessandro N. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. 2006.04.28 Nr.4, p.923-30: <URL: <http://www.ncbi.nlm.nih.gov/pubmed/16525642>> *
Qi Qin, Yi-Wei Lin, Xiang-Yi Zheng, Hong Chen, Qi-Qi Mao, Kai Yang, Shou-Jiang Huang, Zheng-Yan Zhao. RNAa-mediated overexpression of WT1 induces apoptosis in HepG2 cells. World Journal of Surgical Oncology 2012,10:11, p. 1-8 *
Горбунова В. А. Новые цитостатики в лечении злокачественных опухолей. Медицина, 1998, 128с *

Also Published As

Publication number Publication date
MD4300B1 (en) 2014-08-31

Similar Documents

Publication Publication Date Title
PH12016500225A1 (en) Novel quinoline-substituted compound
EA201690598A1 (en) AMINOGETEROARIL BENZAMIDES AS KINASE INHIBITORS
MX2015002616A (en) Synthesis of bis(fluorosulfonyl)imide.
MX350892B (en) Synthesis of antiviral compound.
CR20200276A (en) SULFAMOYLARYLAMIDES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B (DIVISIONAL EXP. 2015-0059)
NZ716840A (en) Combination formulation of two antiviral compounds
BR112014005226A2 (en) benzonitrile derivatives as kinase inhibitors
EA201391822A1 (en) NEW PYRIDINE DERIVATIVES
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
JO3025B1 (en) Oxazole substituted indazoles as pi3 - kinase inhibitors
EA201490747A1 (en) 1-Arylcarbonyl-4-oxypiperidine compounds useful for the treatment of neurodegenerative diseases
EA201390794A1 (en) BICYCLIC COMPOUND
EA201590661A1 (en) AZACHINASOLINE INHIBITORS OF ATYPICAL PROTEINKINASE C
CL2016000382A1 (en) Processes to prepare antiviral compounds
TR201906413T4 (en) Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide.
GEP201606598B (en) Heteroaromatic compounds as dopamine d1 ligands
CR20150245A (en) NEW PROCESS FOR THE PREPARATION OF COMPOUNDS FOR USE IN CANCER TREATMENT
MD4194B1 (en) Trinuclear coordinative compound tris{µ-¢3,5-dibromo-2-hydroxybenzylidene-4′-(pyridin-2-yl)-thiosemicarbazido(2-)]copper}hydrate, exhibiting antifungal activity against Candida albicans
MX338885B (en) Compounds useful in the synthesis of benzamide compounds.
MX2014004920A (en) Novel pyrazine derivatives.
EA201591498A1 (en) AZETIDINYLOXYPHENYLPYRROLIDINE COMPOUNDS
MX2015012318A (en) Solid state forms of a quinazoline derivative and its use as a braf inhibitor.
IN2014DN10198A (en)
EA201401277A1 (en) METHANTION COMPOUNDS WITH ANTI-VIRUS ACTIVITY
MD4300C1 (en) Inhibitor of HepG2 cell proliferation in liver cancer based on chloro-[2-phenyl(pyridine-2-yl)methanone-4-(3-methoxyphenyl)thiosemicarbazono]nickel

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees